SCM Lifescience

Incheon, South Korea Founded: 2014 • Age: 12 yrs
Mesenchymal stem cells are developed for therapeutics using proprietary methods.
Request Access

About SCM Lifescience

SCM Lifescience is a company based in Incheon (South Korea) founded in 2014 by Sun U Song.. SCM Lifescience has raised $4.8 million across 1 funding round from investors including Duopharma Biotech Berhad. The company has 56 employees as of December 31, 2024. SCM Lifescience has completed 1 acquisition, including Argos Therapeutics. SCM Lifescience offers products and services including Stem Cell Therapy, Immune Cell Therapy, Tissue Engineering Therapy, and Enseria Cosmetics. SCM Lifescience operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.

  • Headquarter Incheon, South Korea
  • Employees 56 as on 31 Dec, 2024
  • Founders Sun U Song
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Scm Lifescience Co., Ltd
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $559.27 K (USD)
    18.56
    as on Dec 31, 2024
  • Net Profit
    $-8.39 M (USD)
    48.35
    as on Dec 31, 2024
  • EBITDA
    $-7.09 M (USD)
    14.06
    as on Dec 31, 2024
  • Total Equity Funding
    $4.8 M (USD)

    in 1 rounds

  • Latest Funding Round
    $4.8 M (USD), Series A

    Oct 26, 2018

  • Investors
  • Employee Count
    56

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of SCM Lifescience

SCM Lifescience is a publicly listed company on the KRX with ticker symbol 298060 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 298060 . Sector: Health technology · South Korea

Products & Services of SCM Lifescience

SCM Lifescience offers a comprehensive portfolio of products and services, including Stem Cell Therapy, Immune Cell Therapy, Tissue Engineering Therapy, and Enseria Cosmetics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

High-purity stem cells for treating incurable diseases.

Advanced immune cell treatments for disease management.

Cell-based solutions for tissue repair and regeneration.

Stem cell-derived skincare for consumer use.

Funding Insights of SCM Lifescience

SCM Lifescience has successfully raised a total of $4.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.8 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $4.8M
  • First Round

    (26 Oct 2018)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2018 Amount Series A - SCM Lifescience Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SCM Lifescience

SCM Lifescience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Duopharma Biotech Berhad. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SCM Lifescience

SCM Lifescience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Argos Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
An online gambling platform is operated for Tai Xiu games.
1997
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - SCM Lifescience

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Scm Lifescience Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SCM Lifescience

SCM Lifescience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Therapies for immunological and neurological disorders are developed.
domain founded_year HQ Location
Plasma-derived therapies are developed to treat multiple diseases.
domain founded_year HQ Location
Small molecule protein degraders are developed for various disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Developer of novel protein-based therapeutics using machine learning and biological engineering
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Scm Lifescience

Frequently Asked Questions about SCM Lifescience

When was SCM Lifescience founded?

SCM Lifescience was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Where is SCM Lifescience located?

SCM Lifescience is headquartered in Incheon, South Korea.

Who is the current CEO of SCM Lifescience?

Byong Kwan Son is the current CEO of SCM Lifescience.

Is SCM Lifescience a funded company?

SCM Lifescience is a funded company, having raised a total of $4.8M across 1 funding round to date. The company's 1st funding round was a Series A of $4.8M, raised on Oct 26, 2018.

How many employees does SCM Lifescience have?

As of Dec 31, 2024, the latest employee count at SCM Lifescience is 56.

What is the annual revenue of SCM Lifescience?

Annual revenue of SCM Lifescience is $559.27K as on Dec 31, 2024.

What does SCM Lifescience do?

SCM Lifescience develops stem cell therapeutics and related services. The company uses a proprietary subfractionation culturing method (SCM) to isolate mesenchymal stem cells (MSCs) from adipose tissue, bone marrow and periodontal ligaments. The procedure produces MSCs that are non-immunogenic in nature, and thus can be used as universal donor cells. SCM is investigating MSC therapeutics for indications like immune-related or inflammatory diseases such as graft-versus host disease, atopic dermatitis and pancreatitis. In addition, the company also offers CMO services for stem cell production and clonal stem cell banking services.

Who are the top competitors of SCM Lifescience?

SCM Lifescience's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.

What products or services does SCM Lifescience offer?

SCM Lifescience offers Stem Cell Therapy, Immune Cell Therapy, Tissue Engineering Therapy, and Enseria Cosmetics.

Is SCM Lifescience publicly traded?

Yes, SCM Lifescience is publicly traded on KRX under the ticker symbol 298060.

How many acquisitions has SCM Lifescience made?

SCM Lifescience has made 1 acquisition, including Argos Therapeutics.

Who are SCM Lifescience's investors?

SCM Lifescience has 1 investor. Key investors include Duopharma Biotech Berhad.

What is SCM Lifescience's ticker symbol?

The ticker symbol of SCM Lifescience is 298060 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available